Patents by Inventor Alexander J. Pickrell

Alexander J. Pickrell has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Apelin polypeptides
    Patent number: 11807693
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Grant
    Filed: January 28, 2021
    Date of Patent: November 7, 2023
    Assignee: AMGEN INC.
    Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John Gordon Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11766436
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: June 30, 2021
    Date of Patent: September 26, 2023
    Assignee: Amgen Inc.
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • NOVEL PRMT5 INHIBITORS
    Publication number: 20230159510
    Abstract: Described herein are compounds of Formula I and pharmaceutically acceptable salt thereof, stereoisomers, tautomers as well as pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting PRMT5 activity and may have use in treating proliferative, metabolic and blood disorders.
    Type: Application
    Filed: February 11, 2021
    Publication date: May 25, 2023
    Applicant: AMGEN INC.
    Inventors: Jennifer Rebecca ALLEN, Albert AMEGADZIE, Diane Jennifer BEYLKIN, Shon BOOKER, Matthew Paul BOURBEAU, John R. BUTLER, Michael J. FROHN, Sanne Ormholt Schroder GLAD, Birgitte Weinreich HUSEMOEN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Qingyian LIU, Patricia LOPEZ, Vu Van MA, Francesco MANONI, Jose MEDINA, Ana Elena MINATTI, Jorge PEIRO CADAHIA, Liping PETTUS, Alexander J. PICKRELL, Ian SARVARY, Nuria A. TAMAYO, Mikkel VESTERGAARD
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220395504
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: June 30, 2021
    Publication date: December 15, 2022
    Inventors: John Gordon ALLEN, Jennifer Rebecca ALLEN, Ana Elena MINATTI, Qiufen XUE, Ryan Paul WURZ, Christopher M. TEGLEY, Alexander J. PICKRELL, Thomas T. NGUYEN, Vu Van MA, Patricia LOPEZ, Longbin LIU, David John KOPECKY, Michael J. FROHN, Ning CHEN, Jian Jeffrey CHEN, Aaron C. SIEGMUND, Albert AMEGADZIE, Nuria A. TAMAYO, Shon BOOKER, Clifford GOODMAN, Mary WALTON, Nobuko NISHIMURA, Youngsook SHIN, Jonathan D. LOW, Victor J. CEE, Anthony B. REED, Hui-Ling WANG, Brian Alan LANMAN
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220175782
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: January 19, 2022
    Publication date: June 9, 2022
    Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon BOOKER, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20220168280
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: January 31, 2022
    Publication date: June 2, 2022
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11285135
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors of Formula I and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: November 5, 2019
    Date of Patent: March 29, 2022
    Assignee: AMGEN INC.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • Substituted piperazines as KRAS G12C inhibitors
    Patent number: 11285156
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: June 11, 2019
    Date of Patent: March 29, 2022
    Assignee: AMGEN INC.
    Inventors: John Gordon Allen, Brian Alan Lanman, Jian Chen, Anthony B. Reed, Victor J. Cee, Longbin Liu, Patricia Lopez, Ryan Paul Wurz, Thomas T. Nguyen, Shon Booker, Jennifer Rebecca Allen, Margaret Chu-Moyer, Albert Amegadzie, Ning Chen, Clifford Goodman, Jonathan D. Low, Vu Van Ma, Ana Elena Minatti, Nobuko Nishimura, Alexander J. Pickrell, Hui-Ling Wang, Youngsook Shin, Aaron C. Siegmund, Kevin C. Yang, Nuria A. Tamayo, Mary Walton, Qiufen Xue
  • Compounds that inhibits MCL-1 protein
    Patent number: 11224601
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: September 23, 2020
    Date of Patent: January 18, 2022
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • APELIN POLYPEPTIDES
    Publication number: 20210261619
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Application
    Filed: January 28, 2021
    Publication date: August 26, 2021
    Inventors: Jerry Ryan HOLDER, Gayathri SWAMINATH, Michael J. FROHN, Brian Alan LANMAN, Anthony B. REED, Leslie P. MIRANDA, John Gordon ALLEN, Alexander J. PICKRELL, Aaron C. SIEGMUND, Lewis D. PENNINGTON, Bryant YANG
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 11090304
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: May 3, 2019
    Date of Patent: August 17, 2021
    Assignee: Amgen Inc.
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman
  • Apelin polypeptides
    Patent number: 10941182
    Abstract: The invention provides modified apelin polypeptides having increased stability, circulating half-life, and/or potency relative to the native apelin-13 polypeptide. Compositions comprising the modified apelin polypeptides and methods of using the polypeptides for treating cardiac disorders, such as heart failure, are also disclosed.
    Type: Grant
    Filed: June 10, 2015
    Date of Patent: March 9, 2021
    Assignee: Amgen Inc.
    Inventors: Jerry Ryan Holder, Gayathri Swaminath, Michael J. Frohn, Brian Alan Lanman, Anthony B. Reed, Leslie P. Miranda, John G. Allen, Alexander J. Pickrell, Aaron C. Siegmund, Lewis D. Pennington, Bryant Yang
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10821115
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 3, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20200171043
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: February 6, 2020
    Publication date: June 4, 2020
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • Compounds that inhibit Mcl-1 protein
    Patent number: 10632128
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Grant
    Filed: August 22, 2019
    Date of Patent: April 28, 2020
    Assignee: AMGEN INC.
    Inventors: Paul E. Harrington, Kate Ashton, Sean P. Brown, Matthew R. Kaller, Todd J. Kohn, Brian Alan Lanman, Kexue Li, Yunxiao Li, Jonathan D. Low, Ana Elena Minatti, Alexander J. Pickrell, Markian M. Stec, Joshua Taygerly
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20200069657
    Abstract: Provided herein are methods of treating cancer with KRAS G12C inhibitors and compositions of the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: November 5, 2019
    Publication date: March 5, 2020
    Applicant: AMGEN INC.
    Inventors: Brian Alan LANMAN, Victor J. CEE, Alexander J. PICKRELL, Anthony B. REED, Kevin C. YANG, David John KOPECKY, Hui-Ling WANG, Patricia LOPEZ, Kate ASHTON, Shon BOOKER, Christopher M. TEGLEY
  • KRAS G12C inhibitors and methods of using the same
    Patent number: 10532042
    Abstract: Provided herein are KRAS G12C inhibitors, compounds of formula (II), or a pharmaceutically acceptable salt thereof: compositions of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: January 14, 2020
    Assignee: Amgen Inc.
    Inventors: Brian Alan Lanman, Victor J. Cee, Alexander J. Pickrell, Anthony B. Reed, Kevin C. Yang, David John Kopecky, Hui-Ling Wang, Patricia Lopez, Kate Ashton, Shon Booker, Christopher M. Tegley
  • COMPOUNDS THAT INHIBIT MCL-1 PROTEIN
    Publication number: 20190381064
    Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, or a stereoisomer thereof; and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.
    Type: Application
    Filed: August 22, 2019
    Publication date: December 19, 2019
    Applicant: AMGEN INC.
    Inventors: Paul E. HARRINGTON, Kate ASHTON, Sean P. BROWN, Matthew R. KALLER, Todd J. KOHN, Brian Alan LANMAN, Kexue LI, Yunxiao LI, Jonathan D. LOW, Ana Elena MINATTI, Alexander J. PICKRELL, Markian M. STEC, Joshua TAYGERLY
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190374542
    Abstract: Provided herein are KRAS G12C inhibitors, such as composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: June 11, 2019
    Publication date: December 12, 2019
    Inventors: John Gordon ALLEN, Brian Alan LANMAN, Jian CHEN, Anthony B. REED, Victor J. CEE, Longbin LIU, Patricia LOPEZ, Ryan Paul WURZ, Thomas T. NGUYEN, Shon Booker, Jennifer Rebecca ALLEN, Margaret CHU-MOYER, Albert AMEGADZIE, Ning CHEN, Clifford GOODMAN, Jonathan D. LOW, Vu Van MA, Ana Elena MINATTI, Nobuko NISHIMURA, Alexander J. PICKRELL, Hui-Ling WANG, Youngsook SHIN, Aaron C. SIEGMUND, Kevin C. YANG, Nuria A. TAMAYO, Mary WALTON, Qiufen XUE
  • KRAS G12C INHIBITORS AND METHODS OF USING THE SAME
    Publication number: 20190343838
    Abstract: Provided herein are KRAS G12C inhibitors, composition of the same, and methods of using the same. These inhibitors are useful for treating a number of disorders, including pancreatic, colorectal, and lung cancers.
    Type: Application
    Filed: May 3, 2019
    Publication date: November 14, 2019
    Inventors: John Gordon Allen, Jennifer Rebecca Allen, Ana Elena Minatti, Qiufen Xue, Ryan Paul Wurz, Christopher M. Tegley, Alexander J. Pickrell, Thomas T. Nguyen, Vu Van Ma, Patricia Lopez, Longbin Liu, David John Kopecky, Michael J. Frohn, Ning Chen, Jian Jeffrey Chen, Aaron C. Siegmund, Albert Amegadzie, Nuria A. Tamayo, Shon Booker, Clifford Goodman, Mary Walton, Nobuko Nishimura, Youngsook Shin, Jonathan D. Low, Victor J. Cee, Anthony B. Reed, Hui-Ling Wang, Brian Alan Lanman